Payment overview · 2025
General Payments
$346.37
10 reported records · 5 companies
Healthcare provider profile · identity verified
Youcef Sennour, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · LEBANON, NH · NPI 1053369280
Verified facts
What the public records show
CMS Open Payments records show Youcef Sennour, MD received $346.37 in general payments during 2025 across 10 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 61.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $211.48 | 61.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.41 | 22.4% | 5 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $22.60 | 6.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.87 | 6.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.01 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $211.48 | 2 |
| Food and Beverage | $134.89 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.03 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.38 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 685 | 218 |
| Amlodipine Besylate | Amlodipine Besylate | 602 | 192 |
| Levothyroxine Sodium | Levothyroxine Sodium | 500 | 152 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 478 | 160 |
| Losartan Potassium | Losartan Potassium | 391 | 120 |
| Lisinopril | Lisinopril | 320 | 100 |
| Metformin Hcl | Metformin Hcl | 276 | 87 |
| Simvastatin | Simvastatin | 261 | 79 |
| Carvedilol | Carvedilol | 257 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 68 |
| Furosemide | Furosemide | 201 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 193 | 58 |
| Eliquis | Apixaban | 184 | 57 |
| Gabapentin | Gabapentin | 183 | 59 |
| Omeprazole | Omeprazole | 183 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 62 |
| Trazodone Hcl | Trazodone Hcl | 180 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 51 |
| Potassium Chloride | Potassium Chloride | 152 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 123 | 39 |
| Montelukast Sodium | Montelukast Sodium | 118 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 35 |
| Donepezil Hcl | Donepezil Hcl | 104 | 36 |
| Nifedipine Er | Nifedipine | 101 | 29 |
| Sertraline Hcl | Sertraline Hcl | 101 | 36 |
| Allopurinol | Allopurinol | 93 | 35 |
| Glipizide | Glipizide | 93 | 33 |
| Ozempic | Semaglutide | 92 | 19 |
| Azithromycin | Azithromycin | 90 | 86 |
| Alprazolam | Alprazolam | 88 | 33 |
| Alendronate Sodium | Alendronate Sodium | 86 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 86 | 24 |
| Meloxicam | Meloxicam | 82 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 23 |
| Ezetimibe | Ezetimibe | 76 | 25 |
| Finasteride | Finasteride | 74 | 19 |
| Spironolactone | Spironolactone | 74 | 28 |
| Metformin Hcl Er | Metformin Hcl | 71 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 66 | 36 |
| Glipizide Er | Glipizide | 66 | 21 |
| Januvia | Sitagliptin Phosphate | 66 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 36 |
| Glimepiride | Glimepiride | 64 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 20 |
| Cefdinir | Cefdinir | 59 | 50 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 59 | 21 |
| Tramadol Hcl | Tramadol Hcl | 56 | 18 |
| Lansoprazole | Lansoprazole | 54 | 16 |
| Synthroid | Levothyroxine Sodium | 54 | 17 |
| Celecoxib | Celecoxib | 53 | 20 |
| Lorazepam | Lorazepam | 53 | 16 |
| Valsartan | Valsartan | 53 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 31 |
| Xarelto | Rivaroxaban | 50 | 12 |
| Famotidine | Famotidine | 48 | 15 |
| Mirtazapine | Mirtazapine | 48 | 22 |
| Ibuprofen | Ibuprofen | 47 | 19 |
| Bupropion Xl | Bupropion Hcl | 44 | 13 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 14 |
| Memantine Hcl | Memantine Hcl | 39 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 13 |
| Atenolol | Atenolol | 35 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 18 |
| Methocarbamol | Methocarbamol | 32 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 27 |
| Nystatin | Nystatin | 31 | 16 |
| Valacyclovir | Valacyclovir Hcl | 31 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Torsemide | Torsemide | 27 | 11 |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Prednisone | Prednisone | 24 | 19 |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Metronidazole | Metronidazole | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 13 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $346.37 · 10 records | Teva Pharmaceuticals USA, Inc. | AMYVID, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, KISUNLA, Ozempic, Rybelsus, Veozah, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error